Regeneron falls after appeals court ruling in Eylea case (update)
Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen ...
pharmaphorum3d
After earlier rejection, high-dose Eylea clears FDA
In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...
Hosted on MSN1mon
Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise
with analysts noting that approximately 80% of Eylea franchise revenues still come from the original 2mg formulation. This gradual shift has raised concerns about the franchise's ability to ...
Yahoo Finance25d
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.